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KINETIK DAN PERMODELAN UNTUK PENGHASILAN  
ASID (S)-IBUPROFEN 
 
 
ABSTRAK 
 
 
Kesan pelarut sampingan dan bes telah dikaji dalam lipase Candida rugosa 
(CRL) sebagai pemangkin hidrolisis (R,S)-2-etoksietil ibuprofen ester di dalam 
media dwi-fasa air-isooktana. Nilai log P yang tinggi dan nilai pKa yang rendah bagi 
pelarut sampingan telah mengurangkan kadar tindakbalas untuk penghasilan asid (S)-
ibuprofen. Tambahan pula, proses hidrolisis menunjukkan  prestasi optimum pada 
hanya 2% (v/v) dimetil sulfoksida (DMSO) dan pada suhu tindakbalas 30°C. 
Penambahan 2% (v/v) DMSO telah meningkatkan penukaran substrat dan  
peningkatan kepekatan DMSO seterusnya telah mengakibatkan penurunan pada 
kadar tindak balas awal dan penukaran substrat, bagaimanapun memberikan lebihan 
produuk enantiomerik (eeP) yang lebih tinggi. Tambahan pula, perbezaan entalpi 
pengaktifan lebih tinggi di antara (S)- dan (R)-2-etoksietil ibuprofen ester di dalam 
media dengan 2% (v/v) DMSO telah mengakibatkan kepemilihan enantiomer yang 
lebih tinggi. Selain daripada itu, kehadiran DMSO telah meningkatkan kestabilan 
CRL pada kepekatan substrat yang lebih tinggi di dalam hidrolisis (R,S)-2-etoksietil 
ibuprofen ester.  
 
Satu model kinetik menggambarkan tingkah laku CRL di dalam hidrolisis (R, 
S)-2-etoksietil ibuprofen ester telah berjaya dihasilkan dengan mengambil kira 
xxi 
perencat tanpa persaingan (2-etoksietanol), perencat substrat tiada tandingan ((S)-2-
etoksietil ibuprofen ester) dan perencat substrat kompetitif ((R)-2-etoksietil ibuprofen 
ester). Model kinetik telah disahkan dan mampu menganggar pemalar kinetik. 
Didapati bahawa, DMSO telah mengurangkan pemalar Michaelis (KMA=384 mM), 
kadar tindakbalas maksimum (VAmax=4.5 mM/hr) dan pemalar perencat bagi perencat 
produk tanpa persaingan (KIP=140 mM), sementara itu pemalar perencat bagi  
perencat substrat tiada tandingan (KISS=1950 mM) telah ditingkatkan.  
 
Di dalam peraseman (R)-2-etoksietil ibuprofen ester, resin OH- ialah 
pemangkin bes paling sesuai berbanding dengan natrium hidroksida (NaOH). 
Bagaimanapun, dengan menggunakan trioktilamina (TOA) sebagai pemangkin bes, 
tiada tindakbalas peraseman ditunjukkan. Pada umumnya, kadar peraseman 
bertambah dengan peningkatan kepekatan bes, suhu tindakbalas dan kepekatan 
DMSO, sementara dengan menggunakan kepekatan substrat yang rendah. Satu 
model kinetik bagi peraseman bermangkinkan bes telah dibangunkan dengan 
menggabungkan kesan kepekatan bes dan substrat awal. Nilai pemalar peraseman 
(krac) telah diperolehi dengan menggunakan dua set data pada keadaan kepekatan 
asas dan substrat awal yang tetap. Model kinetik peraseman bermangkinkan bes 
dengan nilai pemalar peraseman krac=0.48 hr-1 telah berjaya disahkan dengan nilai 
R2=0.98. 
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KINETICS AND MODELLING FOR THE PRODUCTION OF  
(S)-IBUPROFEN ACID 
 
 
ABSTRACT 
 
 
The effect of co-solvents and bases have been investigated in Candida rugosa 
lipase (CRL)-catalyzed hydrolysis of (R,S)-2-ethoxyethyl ibuprofen ester in biphasic 
water-isooctane medium. A high log P and low pKa values of co-solvent has reduced 
the reaction rate for the production of (S)-ibuprofen acid. Moreover, the hydrolysis 
process shows an optimum performance at only 2% (v/v) dimethyl sulfoxide 
(DMSO) and at the reaction temperature of 30°C. The addition of 2% (v/v) DMSO 
has increased the conversion of substrate and further increase in the concentration of 
DMSO has resulted in a low initial reaction rate and conversion of substrate, 
however gives a high enantiomeric excess of the product (eeP). Additionally, a 
higher differential activation enthalpy between (S)- and (R)-2-ethoxyethyl ibuprofen 
ester in the medium with 2% (v/v) DMSO has resulted in higher enantioselectivity. 
Moreover, the presence of DMSO has increased the CRL stability at higher substrate 
concentration in hydrolysis of (R,S)-2-ethoxyethyl ibuprofen ester. 
 
A kinetic model to describe the behavior of the CRL in hydrolysis of (R,S)-2-
etthoxyethyl ibuprofen ester was successfully developed by accounting the non-
competitive inhibitor (2-ethoxyethanol), uncompetitive substrate inhibitor ((S)-2-
ethoxyethyl ibuprofen ester) and competitive substrate inhibitor ((R)-2-ethoxyethyl 
xxiii 
ibuprofen ester). The kinetic model was validated and able to estimate the kinetic 
constants. It has been found that, DMSO has reduced the Michaelis constant 
(KMA=384 mM), the maximum reaction rate (VAmax=4.5 mM/hr) and the inhibitors 
constant of non-competitive product inhibitor (KIP=140 mM), meanwhile the 
inhibitor constant of an uncompetitive substrate inhibitor (KISS=1950 mM) was 
increased.  
 
In the racemization of (R)-2-ethoxyethyl ibuprofen ester, OH- resin is the 
most suitable base catalyst compared to sodium hydroxide (NaOH). However, by 
using triocthylamine (TOA) as base catalyst, racemization reaction was not 
indicated. Generally, the racemization rate is faster with increases base 
concentration, reaction temperature and concentration of DMSO, while using low 
substrate concentration. A kinetic model of base-catalyzed racemization was 
developed incorporating with the effect of base-concentration and initial substrate 
concentration. The racemization constant (krac) value was obtained by using two sets 
of experimental data at fixed base and initial substrate concentrations. The kinetic 
model of base-catalyzed racemization with a racemization constant of krac=0.48 hr-1 
was successfully validated with a value of R2=0.98. 
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CHAPTER 1 
INTRODUCTION 
 
 
 
1.1 Rationale For Single Enantiomer Drug 
 
A racemic drug is an equimolar mixture with distinct pharmacokinetic and 
pharmacodynamic properties. Compared with the active enantiomer, the inactive 
enantiomer in a racemic mixture often has different rates of absorption, metabolism, 
and excretion, as well as different affinities for tissue receptor and protein receptor 
binding sites. It may be an agonist or antagonist, produce adverse effects, increase 
efficacy, or place an undue burden on clearance mechanisms. For example, (S)-
ibuprofen is over 160-fold more potent, and inhibitor of cyclo-oxygenase I than (R)-
ibuprofen (Adams et al., 1976). Meanwhile, (S)-citalopram is over 100-fold more 
potent as an inhibitor of the Serotonin Reuptake Transporter than (R)-citalopram 
(Somogyi et al., 2004). 
 
Since the pharmacokinetics of both enantiomers differ, the contribution of each 
enantiomer in term of specific therapeutic effect and toxicity need to be considered 
before the products can be marketed. For example, the enantiomers of α-
propoxyphene, the (+)-enantiomer of α-propoxyphene is a potent analgesic drug, 
whereas the (-)-enantiomer is a potent antitussive agent (an agent that suppresses 
coughing) devoid of analgesic activity (Eichelbaum et al., 1996). The different 
spectrum was documented on the pharmacological effects of the enantiomers of α-
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dextropropoxyphene resulted in the development of two separate stereochemically 
pure drugs: α-dextropropoxyphene (Darvon), an analgesic (pain relieving), and α-
levopropoxyphene (Novrad), an antitussive. 
 
 
1.2 Market Survey 
 
Single enantiomer drug sales show a continuous growth worldwide and many 
of the top selling drugs are marketed as single enantiomers (Shafaati, 2007). 
According to an annual report from Medicinal Chemistry, 754 new drugs (new 
chemical and biological entities) were launched in the world within 20 years 
covering between 1985 and 2004 (Murakami, 2007). The most prominent 
observations are the increase of single enantiomers lunched and the decrease of 
racemates, which at the beginning dominated two-thirds of the market in 1985. The 
increase of single enantiomers lunched from 24 to 44% of marketed drugs within that 
period from 1985 to 2004 showed an increase of interest towards single enantiomers 
in pharmaceutical industries rather than chirals. 
 
Single enantiomer therapeutic had sales of USD 225 billion in 2005 (Table 
1.1). This figure represents 37% of the total final formulation pharmaceutical market 
of USD 602 billion. The annual growth rate of a single enantiomer product for the 
past 5 years was 11%, which is at par with the pharmaceutical market as a whole 
(Erb, 2006). Figure 1.1 shows the global pharmaceutical market from 2006 to 2013. 
According to a report conducted by Business Communications Company (BCC) 
research, the global market for pharmaceuticals increased from USD 693.7 billion in 
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2007 to USD 737.6 billion by the end of 2008. It should reach over USD 1 trillion by 
2013, a Compound Annual Growth Rate (CAGR) of 6.9%. The generic perception 
drugs segment is expected to experience the highest growth rate over the 2008 to 
2013 period. The market is worth an estimated USD 88.7 billion in 2008 and it is 
expected to reach USD 151.4 billion by the end of 2013 with estimated CAGR of 
11.3%. The future growth of single enantiomer products is expected to be strong 
based on the following key market drivers; 
 
• increased evidence and awareness of improved therapeutic profiles. 
• published policies and guidelines of regulatory agencies. 
• advances in chiral technologies. 
• racemic switches as a generic defense strategy. 
• the need for new and better anticancer and antiviral drugs. 
 
 
Figure 1.1: Global pharmaceutical market 2006 to 2013 (Krishan, 2008). 
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Table 1.1: Worldwide sales of single enantiomer pharmaceutical products final 
formulation (Erb, 2006). 
 
Therapeutic 
category 
2000 sales 
(USD billions) 
2004 sales 
(USD billions) 
2005 sales 
(USD billions) 
CAGR (%) 
2000-2005 
Cardiovascular 27.650 34.033 36.196 6 
Antibiotics and 
antifungals 
25.420 32.305 34.298 6 
Cancer therapies 12.201 21.358 27.172 17 
Hematology 11.989 20.119 22.439 13 
Hormone and 
endocrinology 
15.228 20.608 22.355 8 
Central nervous 
system 
9.322 17.106 18.551 15 
Respiratory 6.506 12.827 14.708 18 
Antiviral 5.890 11.654 14.683 20 
Gastrointestinal 4.171 11.647 13.476 26 
Ophthalmic 2.265 3.063 3.416 9 
Dermatological 1.272 1.486 1.561 4 
Vaccines 1.427 2.450 3.100 17 
Other 7.128 10.400 13.268 13 
Total 130.991 199.056 225.223 11 
 
 
1.3 Ibuprofen 
 
 Iso-butyl-propanoic-phenolic acid or commercially known as ibuprofen, 
belongs to a class of drugs called the non-steroidal anti inflammatory drugs 
(NSAIDs). NSAIDs are any of a large group of drugs that reduce pain and 
inflammation in muscles and joints. Other members of this class include aspirin, 
naproxen (Aleve), indomethacin (Indocin) and nabumetone (Relafen). These drugs 
are used for the management of mild to moderate pain, fever and inflammation. 
These symptoms are promoted by the release of chemicals in the body called 
prostaglandins. Ibuprofen blocks the enzyme that makes prostaglandins 
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(cyclooxygenase), resulting in lower levels of the molecules (Jensen, 2002). As a 
consequence, inflammation, pain and fever are reduced. 
 
Ibuprofen contains a chiral carbon in the α-position of the propionate 
structure (Agatonovic-Kustrin et al., 2000). As such, there are two possible 
enantiomers of ibuprofen with different potential in terms of inversion and 
bioavailability (Cheng et al., 1994). Due to the high cost of purification process, for 
high enantiomeric ibuprofen in the most prescriptions, the drug is normally 
prescribed in the form of racemic ibuprofen (Figure 1.2).  
 
COOH
H
Ph
H3C
COOH
Ph
H
H3C
CH3
CH3
COOH
H
H3C
*
Ibuprofen acid
(R)-configuration (S)-configuration  
Figure 1.2: Racemic structure of (R)- and (S)-ibuprofen acid (* represent the position 
of the chiral carbon). 
 
Currently the separation of an enantiomeric compound has been studied in 
order to produce optically pure enantiomers, instead of producing racemic mixtures. 
A multitude of methods and techniques for the separation of enantiomers exists such 
as asymmetric biotransformation, capillary electrophoresis, chromatography, liquid-
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liquid extraction, membrane separation and crystallization (Maier et al., 2001; 
Carvalho et al., 2006). For each method, several advantages and disadvantages 
prevail, depending upon factors such as time, purity, chemical processing, and 
inherent side reactions. A large investment has been made in research to develop 
specific techniques, particularly for (S)-ibuprofen production. 
 
Kinetic resolution for the production of (S)-ibuprofen acid has been intensely 
investigated. Various ibuprofen ester derivatives have been tested such as methyl 
ibuprofen ester, ibuprofen trifluroethyl ester, 2-ethoxyethyl ibuprofen ester and other 
types of esters. However, the reaction slows down after reaching 50% where the less 
reactive enantiomer remained. However, with the availability of racemization 
process, the conversion of substrate could reach 100%. Kinetic resolution and 
racemization are suitable to be applied in parallel for (S)-ibuprofen production. The 
racemization processs will be discussed further in the next chapter. 
 
 
1.4 Problem Statement 
 
Hydrolysis or kinetic resolution of ibuprofen ester by lipase-catalyzed reaction 
has become a method of interest to isolate pure (S)-ibuprofen acid from its racemic 
compound.  The production of (S)-ibuprofen acid was tested in the enzymatic 
membrane reactor by giving 85% eep, 31% ees and E=13 of enantiomeric ratio (Long 
et al., 2005b). The performance of kinetic resolution of (S)-ibuprofen was further 
improved by integrating the resolution with racemization process or so called 
dynamic kinetic resolution (DKR). The DKR of (S)-ibuprofen acid was conducted in 
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a batch reactor giving 84% substrate conversion and 99.4% of enantiomerically pure 
(S)-ibuprofen (Fazlena et al., 2006). 
 
In the kinetic resolution of ibuprofen ester in enzymatic membrane reactor, the 
product (S)-ibuprofen acid is simultaneously separated from the substrate solution. 
However, the maximum conversion is limited for only 50%. For the DKR in batch 
reactor, the conversion was exceeding 50% as its involved in-situ racemization 
(Fazlena et al., 2006). Hence, the DKR technique in an enzymatic reactor should be 
the answer for the production of (S)-ibuprofen acid. This configuration will give a 
comparatively high conversion, high optically pure single enantiomer and simplified 
downstream processing for the product purification. However, another matter that 
needs to be considered in the DKR is the compatibility of hydrolysis and 
racemization processes. In-situ racemization will occur when there was an untreated 
substrate or undesired enantiomer. The undesired enantiomer will be converted to the 
desired enantiomer in racemic form, until an equilibrium is reached. However, the 
rate of hydrolysis will be hindered by racemization process as this process occurs in 
a slow reaction rate. Hence it will be a limiting factor to the hydrolysis rate. In order 
to obtain a fast conversion of substrate, racemization rate should be increased, since 
the product from the racemization will be used as a substrate for the hydrolysis 
process. If the racemization rate could not satisfy hydrolysis substrate demand, the 
time taken for 100% conversion of (R,S)-ester to (S)-acid will be time consuming. 
The use of co-solvents or additives in DKR could substantially increase the reaction 
rate  (Fazlena et al., 2006).  
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Additionally, in DKR, the compatibility of the hydrolysis and racemization 
reaction condition should be paid more attention. Since enzyme is very sensitive 
towards reaction environment, the choice of catalyst and co-solvent for racemization 
must not affect the optical purity of the product, enzyme selectivity and enzyme 
stability. Strong base such as sodium hydroxide already showed a great potential in 
DKR of ibuprofen ester (Fazlena et al., 2006). However, the presence of sodium 
hydroxide will change the reaction medium to a highly basic condition (>pH 9). It is 
rule of thumb that, the pH needs to be maintained according to the optimum 
condition for the enzyme (Candida rugosa lipase). An addition of the buffering agent 
could maintain the pH, and yet increase the ionic strength of the reaction medium. A 
minimal concentration of both buffering agent and sodium hydroxide should be used 
in order to avoid any additional effect caused by ionic compounds. Another 
alternative is to use an amine compound as a racemization catalyst. The study on the 
performance of amine in the racemization of ibuprofen ester is yet to be verified and 
the result is particularly important in order to determine the effectiveness of amine as 
base catalyst. Additionally, amine base such as triocthylamine is highly hydrophobic 
and suitable to be applied as base catalyst in the shell side of the enzymatic 
membrane reactor. This is advantageous, since the effect of base on enzyme 
immobilized in membrane porous could be minimized. However, it is a challenge to 
increase anion dissociation of triocthylamine with base dissociation constant value 
less than sodium hydroxide. The base anion in its free form is important to increase 
the base reactivity and the formation of carbanion for racemization process (Ebbers 
et al., 1997).  
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Hence, in this study, the performance of the base catalysts; sodium hydroxide 
and trioctylamine will be explored. Alternative catalyst such as OH- resin consists of 
hydroxide ion shall also be tested. The reaction medium will be added with 
appropriate amount of co-solvents in order to investigate its implications on the 
racemization and hydrolysis processes. The co-solvents are expected to increase the 
conversion, enantiomeric excess and enzyme stability in the hydrolysis as well as to 
facilitate the racemization rate of (R,S)-2-ethoxyethyl ibuprofen ester. 
 
 
1.5 Research Objective 
 
The main objective of this research project is to investigate the feasibilities of 
enzyme and base catalysts as well as the co-solvent in the DKR of ibuprofen ester. 
This research project aims to achieve the following specific objectives: 
 
i. To evaluate the effect of co-solvents in the enzymatic hydrolysis of (R,S)-2-
ethoxyethyl ibuprofen ester. 
 
ii. To evaluate the kinetic behavior of enzyme (Candida rugosa lipase) in the 
presence of dimethyl sulfoxide (DMSO). 
 
iii. To compare the effectiveness of trioctylamine, sodium hydroxide and OH- 
resin in the racemization of (R,S)-2-ethoxyethyl ibuprofen ester. 
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iv. To develop kinetic model, determine the kinetic parameters and validate the 
kinetic model based on the enzymatic mechanism for kinetic resolution and 
racemization of (R,S)-2-ethoxyethyl ibuprofen ester. 
 
 
1.6 Organization of Thesis 
 
This thesis is divided into six chapters as follows;  
 
Chapter 1 gives the introductory of this research project. This chapter starts 
with the pharmaceutical market demand in single enantiomer drugs reported by 
market researcher. It also gives a brief overview of the single enantiomer 
production of (S)-ibuprofen through kinetic resolution. The problem statement 
and objectives of this research project are also clearly stated in this chapter.  
 
Chapter 2 gives the review from the works of other researchers and methods 
applied in the present days for the hydrolysis and racemization of esters. This is 
followed by a discussion on the advantages of using co-solvents in the 
hydrolysis and racemization processes. Reviews on the kinetics, DMSO as co-
solvent and base-catalyzed racemization are also covered in detail. 
 
Chapter 3 describes the methods and analysis required for the hydrolysis and 
racemization processes. It also explains the chemical requirements and 
equipments used throughout the whole process of this study. The subsequent 
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topics describe clearly the methodology of this research project-synthesis using 
Candida rugosa lipase (CRL), co-solvents and base catalysts. 
 
Chapter 4 presents the results obtained from experimental runs and discusses 
on the effect of parameters on the synthesis of (S)-ibuprofen acid. The 
discussion is focused on the co-solvents and bases employed in hydrolysis and 
racemization of ibuprofen ester respectively. 
Chapter 5 presents the kinetic model proposed for hydrolysis and racemization 
of ibuprofen ester. Every kinetic constant was estimated using regression 
method available in MATLAB®. The variation of kinetic parameters obtained 
between previous studies was discussed, beside the validation of the model 
between estimated and experimental data. 
 
Chapter 6 concludes the research project. Recommendations for future work 
related to this research project are also given. 
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CHAPTER 2 
LITERATURE REVIEW 
 
 
 
2.1 Synthesis of Enantiomerically Pure Drug Compounds 
 
There are three possible strategies in the preparation of enantiomerically pure 
drug compounds (Martin-Matute et al., 2008b). One way is through performing a 
resolution of a racemate or known as kinetic resolution where the procedure depends 
on the difference of reaction rates of two enantiomers. Secondly, is to use naturally 
occurring starting materials of defined absolute configuration, provided by nature’s 
chiral pool. The third approach is through asymmetric synthesis, where it involves 
the creation of an asymmetric (stereogenic) center, which in this case, the chiral 
discrimination of equivalent groups in an achiral starting material (prochiral). 
 
For each of these techniques there are some pros and cons. In the first 
method, the maximum theoretical yield gives only 50%. In the second approach, 
chiral pool, suitable naturally occurring chiral compound as starting materials is 
needed. However, most of the commercially available chiral molecules consist of 
carbohydrates and amino acids. Looking for suitable precursor can be difficult 
besides, requiring the multi-step preparation leading to the overall low yields 
(Yazbeck et al., 2004). Meanwhile, asymmetric synthesis has been chosen as the best 
method to date (Martin-Matute et al., 2008b). This method is able to change many 
prochiral molecules via chiral multiplication with a single optically pure enantiomer 
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catalyst. A method for preparation of enantiopure compounds via asymmetric 
synthesis is still growing in numbers, and yet, the kinetic resolution is the most 
suitable method normally employed in the industry. Majority of the cases, enzymes 
are used as biocatalyst (Martin-Matute et al., 2008b). 
 
 
2.2 Kinetic Resolution 
 
Kinetic resolution (KR) can be defined as a partial separation of two 
enantiomers from a racemic mixture and it can transform one of the enantiomers of a 
racemic mixture into a product (enantiopure) rather than its mirror image. KR 
normally occurs based on the reaction rate of the enantiomers. In an ideal condition, 
both enantiomers show different reactivities, one of the enantiomers would react very 
fast to form the product, while its mirror image may react at a slower rate or even no 
reaction (Martin-Matute et al., 2008b). Figure 2.1 below shows the general 
mechanism of the KR; 
 
R Q
kR
PS
kS
Slow
Fast
50%
 
Figure 2.1: General mechanisms for kinetic resolution. 
 
The symbols R and S represent the (R)- and (S)-enantiomer substrate whereas 
P and Q signify the product and by-product produced in the reaction, respectively. 
Meanwhile, the symbols kS and kR correspond to the rate constant for product P and 
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by-product Q, respectively. KR took place when kR ≠ kS and the reaction is stopped 
somewhere between 0 and 100% conversion. Usually the reaction is slowing down 
after 50% conversion is reached. During the reaction, the concentration of both 
enantiomers is not constant, therefore the conversion will affect reaction rate of the 
enantiomers (Martin-Matute et al., 2008b). It is advised that the reaction should be 
stopped when the conversion reached 50% in order to achieve high enantiomeric 
excess. 
 
 
2.3 Racemization 
 
Racemization is defined as the irreversible formation of a racemate from a 
pure enantiomer and linked with the total loss of optical activity (Ebbers et al., 1997). 
A racemate is defined as an equimolar mixture of two enantiomers regardless of their 
physical states (Ebbers et al., 1997). Racemization of the unwanted isomer is 
meaningful in resolution of chiral constituent to exceed the theoretical yield of 50% 
in an enantioselective synthesis.  This would be an attractive option due to the 
current high cost of production of optically pure active pharmaceutical ingredients. 
 
From the literature survey, a number of general chemical processes leading to 
racemization of asymmetric carbon atoms have been known. Most processes 
involved strong basic or acidic reaction conditions at elevated temperatures. The rate 
of racemization can be illustrated as the interconversion rate of enantiomers, or either 
as the rate of formation of the racemate (Ebbers et al., 1997). Racemization method 
has been classified into several methods as reported by Ebbers and co-workers 
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(1997). From all methods shown in Table 2.1, base-catalyzed racemization was the 
most employed technique. 
 
Table 2.1: Racemization methods  
 
Methods Details References 
Base-catalyzed 
racemization 
Applied for compounds bearing acidic 
hydrogen at the chiral center. For instant 
in the racemization of amino acid 
thioester, and profens ester. 
(Chen et al., 2002a; 
D’Arrigo et al., 
2011; Chavez-Flores 
et al., 2012) 
Metal-catalyzed 
racemization 
Feasible for wide range of compounds 
which include; ketones, esters, secondary 
alchohols. However the preparations of 
the metal catalysts are very complex, 
costly and require multi step synthesis. 
(Kim et al., 2002; 
Mahn-Joo Kim et al., 
2007) 
Enzyme-
catalyzed 
racemization 
Applied to racemization of amino acids 
and derivatives and to α-hydroxy-
carboxylic acids and derivatives. For 
instance, Mandelate racemase is employed 
to racemize trifluorolactate. 
(Nagar et al., 2011) 
Thermal 
racemization 
Suitable for compound which racemize by 
rotation or deformation of bond (biaryls), 
phyramidal inversion and rearrangement 
of bonds. For instant, the (+)-10-exo-
hydroxy-
pentacyclo[6.2.1.13,6.02,7.05,9]dodeca-4-
one was able to racemize at elevated 
temperature due to dyotropic 
rearrangement. 
(Martins et al., 2003) 
Acid-catalyzed 
racemization 
Resulted from protonation of α-carbon at 
the chiral center. For instance, (S)-1-
phenylethanol acetate was racemized in 
the presence of acidic resin. 
(Cheng et al., 2010) 
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2.4 Base-Catalyzed Racemization 
 
Up to this moment, base-catalyzed racemization is the most important method 
currently used for racemization of optically pure organic compound. It can be applied 
to almost all compounds bearing acidic hydrogen at the chiral center or α-carbon. In 
DKR of optically active organic compounds such as ibuprofen ester and naproxen 
ester, the substrates contain a proton at chiral center with low pKa value. In DKRs, 
base-catalyzed racemization are categorized according to the nature of the substrates, 
as being thioesters, α-activated esters, oxazolones, hydantoins or acyloins (Martin-
Matute et al., 2008a). Fundamentally, base-catalyzed racemization usually involves 
the removal of a hydrogen ion from the chiral center to form a carbanion. The 
carbanion needs to be stabilized by adjacent groups such as keto, nitrile, nitro or 
other functionalities, or by a reversible elimination of a β-substituent (Figure 2.2) 
(Ebbers et al., 1997). Thus, preparation of a derivative is required to enhance the 
acidity of α-proton. 
 
H
base
L L + L
H
X base X X
X = C(O), CN, 
NO2, etc.
a
b
 
Figure 2.2: Mechanism for base-catalyzed racemization. (a) Carbanion stabilized 
by adjacent groups, and (b) carbanion stabilized by a reversible elimination of a 
β-substituent. 
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Substitution reactions of optically active molecule always involve breaking 
and reforming of bonds at the chiral center. These process sometimes occur 
stereospecifically with retention or inversion of configuration where optical activity 
is preserved (Wiberg, 2001). In other cases, they occur non-stereospecifically, with 
simultaneous inversion and retention of configuration, leading to racemization 
(Wiberg, 2001).  Racemization depends on several parameters such as solvents, 
substituents and characteristic of the bases. The removal of hydrogen by a base in 
non polar solvents results in an intimate ion pair. In these solvents, the re-addition of 
the proton may lead to some preferences for retention and therefore, lead to a 
relatively slow racemization (Ebbers et al., 1997). For a polar solvent, separated ion 
pair is generated, rearrangement of proton (H+) predominantly occurs from the 
opposite side, resulting in a net of inversion and fast racemization (Ebbers et al., 
1997). In addition, bases tend to be more reactive in aprotic polar solvents than in 
protic polar solvents and results in faster racemization. This phenomenon occurs 
because the anions are less solvated in aprotic polar solvents than neutral species or 
cations due to lower acidities. 
 
 
2.5 Dynamic Kinetic Resolution 
 
The DKR is generally used to overcome the disadvantages encountered 
during KR. Previously, KR has been the main route in the enzymatic resolution 
procedure for the synthesis of optically pure compounds. However, with only 50% of 
maximum conversion, the method has driven researchers to switch into the method 
of DKR. The method of DKR, can take place by combining the standard KR and in-
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situ racemization process of the chiral substrates (Figure 2.3). In the standard KR, the 
hydrolysis process took place by means of enantioselective biocatalyst to hydrolyze 
racemic substrate and left unreacted enantiomer. Once the KR is coupled with the in-
situ racemization, the unreacted substrate will be recycled as a racemic mixture. 
Hence, further hydrolysis of substrate can take place and consequently, the 
conversion of 100% of the substrate to single enantiomeric product could be 
achieved. This method has been proven in the field of chiral drugs resolution such as 
naproxen, fenoprofen and ibuprofen (Chen et al., 2002b; Lin et al., 2003; Fazlena et 
al., 2006). DKR has provided highly valuable processes for production of 
enantiomerically pure drugs by converting achiral or racemic drugs compound. 
However, this process is influenced by the specific factor, the parameters which are 
also important include; reaction temperature, solvent type, concentration, base 
catalysts and enzymes (biocatalyst). 
 
Racemization
kRac
R Q
kR
Slow
100%
PS
kS
Fast
 
Figure 2.3: Dynamic kinetic resolution mechanism. 
 
For efficient enzymatic DKR, the following necessities must be satisfied 
(Martin-Matute et al., 2008b); 
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i. The KR must be very selective (E > 20). 
ii. The racemization must be fast, at least 10 times faster than the enzyme 
catalyzed transformation of the slow-reacting enantiomer (krac > 10 
kS). 
iii. The racemization catalyst must not react with the product of the 
reaction. 
iv. The KR and the racemization must be compatible under the same 
reaction conditions. 
 
In an idyllic DKR, where the substrate stays racemic during the reaction, the 
optical purity depends only on the enantiomeric ratio (E), and is independent of the 
extent of conversion. The enantiomeric excess of the product formed under 
racemizing states is identical to the initial enantiomeric excess under non-racemizing 
states (Martin-Matute et al., 2008b). 
 
 
2.6 DKR of α-substituted Carboxylic Acids or Esters 
 
Considerable effort has been made to produce optically pure compound of 
non-steroidal anti-inflammatory drugs through DKR. However, the conversions of 
substrate, usually corresponding to ester derivatives are still in moderate level and 
hardly reaching more than 90%. The previous work on DKR of optically active drug 
productions is presented in Table 2.2. A variety of carboxylic acid derivatives have 
been employed for the resolution of optically active compounds such as thioester, 
methyl ester, ethyl ester and etc.  
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As for a substrate bound with thioesters as a leaving group, the feasibility of 
this approach was pioneered by Drueckhammer and co-workers (Tan et al., 1995). 
The DKR was performed with propionate thioesters bearing a phenylthio group, 
which also contribute to the acidity of α-proton (Tan et al., 1995). The α-protons of 
thioesters are acidic to allow the continuous racemization of the substrate by base-
catalyzed deprotonation at the α-carbon. The enzymatic hydrolysis of the thioester 
was accompanied with a racemization catalyzed by trioctylamine (Figure 2.4). 
Because of the insolubility of the substrate and base catalyst in aqueous medium, 
they employed a biphasis system which is toluene-water mixture. By using 
Pseudomonas cepacia lipase (Amano PS-30) as the enzyme and a catalytic amount 
of trioctylamine, they obtained a quantitative yield of the corresponding carboxylic 
acid in 96.3% ee.  
 
SPh
SEt
O
SPh
SEt
O
SPh
SEt
O
+SPh
OH
O
+ EtSH
Pseudomonas cepacia
Oct3N (0.5 equiv)
Toluene / H2O, 25°C
65hrs
>99% yield, 96.3% ee
 
Figure 2.4: DKR of thioesters using a base for racemization performed by 
Drueckhammer et al. (Tan et al., 1995). 
 
Has been reported that the DKR of naproxen, suprofen and fenoprofen 
thioesters were synthesized using trioctylamine as the base catalyst (Chang et al., 
1999; Lin et al., 2000; Chen et al., 2002b). The corresponding thioesters substrate 
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was prepared with thiophenol or 2,2,2-trifluoroethanethiol. The base catalyst, 
trioctylamine was reported not only functioned for the formation of carbanion in 
racemization, but also helped to activate the lipase (Chang et al., 1999). However, in 
the DKR of suprofen thioesters, increasing the trioctylamine concentration could also 
result in decreasing the enzyme deactivation constant, which implies that 
trioctylamine could enhance the lipase stability (Lin et al., 2000). However, the data 
is not enough to elucidate the statement where trioctylamine can activate and 
increase the activity of enzyme. Therefore, a comprehensive study on the interaction 
between trioctylamine and lipase molecules is still needed. 
 
Another DKR of esters which bears an electron-withdrawing group at the α-
carbon has been reported on the DKR of (R,S)-2,2,2-trifluoroethyl α-chlorophenyl 
acetate in water-saturated isooctane (Wen et al., 2006). Lipase MY from Candida 
rugosa was used for the KR and an addition of trioctylamine which acts as a base for 
racemization (Figure 2.5). The product, (R)-chlorophenylacetic acid was obtained in 
93% yield and 89.5% ee. 
 
Cl
O CF3
Cl
O CF3
+ CF3CH2OHC
andida cylindracea lipase
Oct3N,
Isooctane / H2O, 30°C
4 days 93% yield, 89.5% ee
 
Figure 2.5: DKR of activated esters using a base for racemization. 
 
The DKR carried out using strong base such as sodium hydroxide has also 
been conducted with an impressive conversion and enantiomeric excess. The lipase-
catalyzed DKR of racemic naproxen methyl ester was carried out in a membrane 
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bioreactor (Xin et al., 2001). Tubular silicone rubber membrane was used inside the 
stirred tank reactor to separate the chemical catalytic racemization and biocatalytic 
resolution process in order to avoid incompatibility between in-situ chemical 
racemization with the presence of biocatalyst. Additionally, hydrophilic porous 
semipermeable membrane was used in the bioreactor to overcome product inhibition 
as well as to assist product recovery. The reaction gave 60% conversion and 96% 
enantiomeric excess (eeP) of the desired (S)-naproxen acid. Similar work was also 
reported on the DKR of racemic ibuprofen ester (Fazlena et al., 2006). The 2-
ethoxyethanol was chosen as nucleophiles to give 2-ethoxyethyl-ibuprofen ester as a 
substrate. The substrate was catalyzed by CRL and in-situ racemization was taken 
place with the addition of 0.5 M aqueous sodium hydroxide solution. The reaction 
took place in a biphasic batch reactor with isooctane as a solvent and dimethyl 
sulfoxide (DMSO) as co-solvent. The addition of 20% (v/v) of aprotic polar solvent 
(DMSO) finally gave 86% conversion and 99.4% optical purity of the desired (S)-
ibuprofen acid. 
 
The trend of base catalyst used for the resolution of carboxylic acid is closely 
depending on the substrate derivatives or the leaving group. For a strong 
nucleophiles leaving group such as thioester derivative, weak base such as 
trioctylamine was employed. In contrast for the weak nucleophiles leaving group, 
strong base such as sodium hydroxide was used to catalyze the racemization process. 
This trend might be related to the racemization process for a substrate with low 
acidity at the α-carbon position as reviewed previously.  
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Table 2.2: Dynamic kinetic resolution of optically active drugs. 
 
Substrate Solvent Enzyme Catalyst Conversion eep References 
(R,S)-suprofen 2,2,2-
trifluoroethyl thioester 
Isooctane Lipase Trioctylamine >50% 95% (Lin et al., 2000) 
Tropic acid ethyl ester  Lipase PS Ruthenium, 
Isopropyl acetate  
60-88% 53-92% (Atuu et al., 2007) 
(R,S)-2-ethoxyethyl 
ibuprofen ester  
Isooctane-
water, DMSO 
20% (v/v) 
CRL Sodium hydroxide 86% 99% (Fazlena et al., 2006) 
Naproxen methyl ester Isooctane, 
Tris-HCl  
CRL Sodium hydroxide 60% 96% (Xin et al., 2001) 
(R,S)-naproxen 2,2,2-
trifluoroethyl ester 
Isooctane CRL 1,5,7-
Triazabicyclo[4,4,0]
dec-5-ene (ρ-TBD) 
75.5% 58% (Lin et al., 2003) 
Naproxen 2,2,2-
trifluoroethyl thioester 
Isooctane CRL Trioctylamine >70% 92% (Chang et al., 1999) 
1,2,3,4-
Tetrahydroisoquinoline-1-
carboxylic acid (ethyl 
ester) 
Toluene-
acetonitrile 
(4:1), 1eqiv 
H2O 
CAL-B Dipropylamine 80% 96% (Paal et al., 2007) 
(R,S)-fenoprofen 2,2,2-
trifluoroethyl thioester 
Isooctane Lipase MY Trioctylamine 91% 91% (Chen et al., 2002b) 
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2.7 Enzymes in Organic Solvents 
 
An addition of enzyme in organic solution significantly changes its original 
natural environment as in an aqueous solution. It was found that enzyme, especially 
from the lipase group could retain their activities when placed in low-water media 
(Klibanov, 1990). This finding gives opportunity to substrate, which less soluble in 
aqueous medium such as chiral drugs. The use of organic medium in enzymatic 
catalysis has increased its application in industrial chemistry. The catalysis 
conducted in water medium always being accompanied by side reactions such as 
hydrolysis, racemization, polymerization and decomposition. Furthermore, the 
removal of water is energy consuming due to its large heat of vaporization and high 
boiling point. Biotransformation in organic solvents offers the following advantages 
(Ghanem, 2007); 
 
i. Better overall yield and the recovery of the product is facilitated by the use of 
low-boiling point organic solvents. 
ii. Non-polar substrates are converted at a faster rate, due to their increased 
solubility. 
iii. Microbial contamination is negligible in the case of using living cells in 
biotransformations. 
iv. Deactivation and substrate or product inhibition is minimized. 
v. Side reactions such as unfavorable hydrolysis are largely suppressed. 
vi. Immobilization of enzymes is not required; the enzyme can be recovered by 
simple filtration. 
vii. Denaturation of enzymes is minimized in organic solvents. 
